The hairy cell leukemia market encompasses a range of targeted therapies, immunotherapies, and supportive care products designed to manage this rare B-cell malignancy. Key offerings include purine analogs such as cladribine and pentostatin, monoclonal antibodies like rituximab, and emerging kinase inhibitors that selectively target malignant cells. https://zippy-goat-z7kvvr.mystrikingly.com/blog/hairy-cell-leukemia-market-trends-by-targetedtherapy-advances